Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...

Increasing access to ADHD diagnosis and medication is a good move. But it shouldn’t be the whole plan to address a condition ...

Investing.com -- ATAI Life Sciences (NASDAQ: ATAI) stock surged 29% after the company and its partner Beckley Psytech announced positive topline results from a Phase 2b study of BPL-003 in patients ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Life Sciences (ATAI) stock rises as the company and Beckley Psytech said their psychedelic drug BPL-003 hit main goals in a ...

Struggling with chronic pain and stress? Discover how combining chiropractic care with psychotherapy can create a healing ...